1. Introduction {#sec1}
===============

In the year of 2010, a concept of "ideal cardiovascular health" was put forward, including ideal healthy behavior, such as status of smoking, body mass index, physical activity and diet, and ideal healthy factors, such as blood pressure, blood glucose, and blood lipids \[[@B1]\]. However, the truth was that, in the 2012 global ten main death causes, vascular diseases such as ischemia heart disease and stroke were the first two according to the report of World Health Organization. In addition, the recent Chinese cardiovascular report indicated that there were 290 million cardiovascular disease patients, 270 million hypertension patients, and 7 million stroke patients, and 1 person in every 5 may be a cardiovascular disease patient \[[@B2]\]. In face of such a huge disease burden, prevention and treatment of vascular related diseases are equally important. And from what have been known, the main pathophysiological mechanism of lesions in heart, brain, kidney, and other organs is the blood vessels that supply the above organs suffering from arteriosclerosis, atherosclerosis, stenosis, and occlusion, which lead to impaired vascular function and structure and further lead to the occurrence of adverse cardiovascular events, such as coronary heart disease, stroke, peripheral arterial occlusion, and even sudden death \[[@B3]\]. Therefore, during the progression of vascular disease from risk factors (such as hypertension, abnormal glucose metabolism, and dyslipidemia) to vascular damage to the target organ damage, before the occurrence and development of the end-stage events, it will be of great importance to recognize surrogate endpoints which can accurately and effectively reflect the clinical endpoints. Furthermore, the surrogate endpoints can be delayed and even reversed by lifestyle and drug intervention. Therefore, early evaluation of surrogate endpoints and intervention to prevent or even reverse the occurrence of adverse vascular events have become a hot research topic in the world.

2. Vascular Endothelial Function {#sec2}
================================

Vascular endothelial cells as a layer of single cell interface between blood flow and vessel wall, responding to the stimulation of body fluid, the nerve, especially the hemodynamics, can regulate vascular tone by the synthesis and release of vasoactive substances, regulate platelet function, inflammatory response, and vascular smooth muscle cell growth and migration, and play an important role in the pathogenesis of vascular diseases \[[@B4], [@B5]\]. Vascular endothelial dysfunction is a systemic disorder characterized by reduced nitric oxide or nitric oxide bioavailability and is the first step in the natural process of arteriosclerosis and atherosclerosis, directly relating to numerous vascular diseases. However, endothelial dysfunction can be reversible, which is different from atherosclerosis. Therefore, it has important significance for the prevention and system management and effective intervention by early clinical detection of vascular disease. Vascular endothelial function can be of diagnostic, prognostic, and predictive value \[[@B6]\]; it can be assessed by invasive procedures such as coronary angiography and noninvasive measurement techniques such as flow-mediated dilation (FMD) and finger end volume recording.

2.1. Coronary Angiography {#sec2.1}
-------------------------

Acetylcholine stimulation by coronary angiography is the traditional method of vascular endothelial function detection \[[@B7]\]. It is the gold standard for the detection of vascular endothelial function by precise measurement of coronary blood flow using Doppler guide wire. But the method is an invasive examination and the operation is difficult and time consuming with high cost. At present, it is difficult to carry out widely in clinical practice.

2.2. Flow-Mediated Dilation (FMD) {#sec2.2}
---------------------------------

Doppler ultrasound equipment was used to measure the baseline and cuff released diameter of brachial artery, and FMD was calculated as the rate of brachial artery diameter changes. It reflects the flow-mediated endothelial nitric oxide (NO) release function and is considered as a commonly used noninvasive method. The method is simple, noninvasive, economical and accurate, reproducible, and clinically beneficial for the promotion of early vascular lesion detection \[[@B8]\]. FMD as a surrogate endpoint to assess cardiovascular risk is widely used in clinical studies. Research suggested that brachial artery FMD was a predictor of cardiovascular events \[[@B9]\] and was a predictor of future target organ damage in low-risk patients with essential hypertension \[[@B10]\]. But FMD detection is highly dependent on operator expertise and cannot rule out nerve interference and environmental factors. In addition, ultrasonic imaging is not suitable for high-precision detection, and thus it limits the wide clinical applications of FMD.

2.3. Pulse Amplitude Tonometry- (PAT-) Reactive Hyperemia Index (RHI) {#sec2.3}
---------------------------------------------------------------------

FMD reflects NO-mediated function of conduit brachial artery and is measured by Doppler ultrasound apparatus. Measurement of digital pulse amplitude tonometry (PAT) is based on a technique similar to that of FMD. It uses photoplethysmography to measure pulse wave amplitude (PWA) in the fingers reflecting small vessel microcirculation function and gets the reactive hyperemia index (RHI). RHI is defined as the ratio of postdeflation to baseline pulse amplitude in the hyperemic finger divided by that in the contra-lateral finger \[[@B11]\]. Studies indicated that RHI independently correlated with future cardiovascular events and added incremental clinical significance for risk stratification \[[@B12], [@B13]\]. RHI can also predict patients with ischemic heart disease and it improved risk stratification when added to traditional risk factors \[[@B14], [@B15]\]. However, the finger-tip devices are for one use only, so there is moderate disposable cost for studies \[[@B16]\].

Both brachial FMD and RHI are independent predictors of cardiovascular events and all-cause mortality and both with similar prognostic magnitude \[[@B17], [@B18]\]. RHI reflects the vasodilator function in the microvasculature of the fingers whereas FMD reflects the vasodilator function in large conduit vessels. FMD serves as an index of NO-mediated endothelium-dependent vasodilator function. Unlike FMD measured at the brachial artery, RHI is not entirely caused by NO and only 50% of it was blocked when a nitric oxide synthase specific blocker (L-NAME) was infused into the brachial artery before PAT measurement \[[@B19]\]. The divergence between brachial and digital vascular function emphasizes the possibility that vasodilation may vary significantly with vessel size and location. Arterial physiology across vascular beds may have implications for the utilization of the PAT and FMD test to measure vascular function \[[@B20]\]. Studies showed that FMD had differing relations with cardiovascular risk factors and were nearly uncorrelated with RHI. These results suggest that FMD and RHI provide distinct information regarding vascular function in conduit versus smaller digital vessels \[[@B20], [@B21]\].

Therefore, whether the prognostic values of these 2 methods are independent of each other and whether an endothelial function-guided strategy can provide benefit in improving cardiovascular outcomes need further research to determine \[[@B18]\].

3. Evaluation of Arterial Stiffness {#sec3}
===================================

Arterial stiffness is mainly determined by larger arteries, because the thoracic aorta and abdominal aorta contribute the greatest to arterial buffering function. Elastic properties of conduit arteries vary along the arterial tree, with proximal arteries being more elastic and distal ones stiffer. In addition, aging and blood pressure are the major determinants of arterial stiffness, which causes a decrease in elastic protein synthesis and an increase in degradation, while the synthesis of type 3 and type 1 collagen is increased and the degradation is reduced \[[@B22]\]. Studies have shown that changes in arterial structure can be quantified in accordance with vascular stiffness and epidemiological studies have indicated that arteriosclerosis is a risk factor for cardiovascular disease progression and is a strong independent predictor of cardiovascular disease and total mortality \[[@B23]\]. Many techniques can be used as assessment of vessel, including assessment of arterial stiffness, as well as the evaluation of subclinical atherosclerosis. This review will carry on a summary on the application of arterial sclerosis detection technologies according to the method of detection, clinical significance, and application value.

3.1. Pulse Wave Velocity (PWV) {#sec3.1}
------------------------------

PWV is a common indicator of arterial stiffness and can be obtained by measurement of distance and pulse wave transit time between two points of vessels \[[@B8]\]. It can be measured by ultrasonic equipment or blood vessel detection equipment automatically and can measure different arterial segments, such as carotid femoral artery, carotid radial artery, carotid dorsal artery, and brachial ankle artery. Application of noninvasive arteriosclerosis detection device can automatically detect PWV, with the advantages of simple operation and good repeatability, but is vulnerable to the impact of immediate blood pressure. Among them, carotid femoral pulse wave velocity (CF-PWV) is considered to be the gold standard for assessment of large artery stiffness \[[@B23]\]. Studies have shown that higher arterial stiffness was significantly correlated with increased subclinical disease burden of coronary artery, lower extremity artery, and cerebral artery \[[@B24]\]. It is not only a manifestation of vascular aging but also a predictor of cardiovascular disease risk \[[@B27]--[@B26]\] and is an independent predictor of functional outcome in patients with acute ischemic stroke \[[@B28]\]. In addition, Framingham study found that in people with higher aortic stiffness the risk of cardiovascular disease increased by 48%, and adding PWV to the standard risk model can improve the risk prediction value of cardiovascular events (such as myocardial infarction, unstable angina, heart failure, and stroke) \[[@B27]\].

3.2. Cardio Ankle Vascular Index (CAVI) {#sec3.2}
---------------------------------------

CAVI is a new evaluation index of arterial stiffness in recent years and can also be measured by means of arteriosclerosis detection device. Compared with PWV, CAVI does not depend on the immediate effect of blood pressure. CAVI comes from the stiffness coefficient *β* and can be calculated by the electrocardiogram, phonocardiogram, and brachial ankle artery pulse waveform and pulse waveform records and is mainly related to aortic stiffness and compliance \[[@B29]\]. A series of studies have found that CAVI as a new marker of vascular health was closely related to arterial injury in patients with hypertension, diabetes, metabolic syndrome, and blood lipid disorder and became a useful tool for health screening because of the blood pressure dependence \[[@B30]--[@B35]\]. In addition, higher CAVI was also associated with lower executive function in older adults \[[@B36]\], and CAVI was also an effective predictor of cardiovascular events in obese patients \[[@B37]\]. In addition, a new classification of vascular health has regarded CAVI as an important evaluation index of vessel in clinical practice \[[@B38]\].

3.3. Other Assessment of Arterial Stiffness {#sec3.3}
-------------------------------------------

Central aortic pressure (CAP) can be measured by invasive cardiac catheterization and noninvasive applanation tonometry of the radial or carotid artery \[[@B39], [@B40]\]. CAP waveforms were determined by a mathematical transformation of the radial waveform or directly ascertained from the carotid arterial pressure waveforms obtained by noninvasive applanation tonometry \[[@B41], [@B42]\]. Most used was noninvasive radial tonometry to acquire waveforms to derive CAP. And CAP can be estimated noninvasively using an automated tonometer device and showed good validity as evaluated by the catheter method \[[@B43]\]. CAP can reflect the load of left ventricle, coronary artery, and cerebral blood vessels more directly and accurately, so it is more significant than the brachial artery pressure. The study found that the level of CAP was related to subclinical organ damage in the heart and is independent of the cardiovascular risk factors \[[@B44]\]. It showed that central but not brachial blood pressure can predict cardiovascular events in an unselected geriatric population \[[@B45]\]. However, guidelines considered that, despite the growing interest in some indirectly various methods, more investigation is needed before recommending the routine measurement of central blood pressure for clinical use \[[@B46]\].

Augmentation index (AI) was obtained from the synthesized aortic pressure waveform \[[@B41]\]. AI, measured using radial artery pulse wave analysis, was defined as the difference between the second and the first systolic peaks of the central arterial waveform, expressed as the percentage of central pulse pressure \[[@B47]\]. It provides a composite measure of aortic elasticity plus muscle artery stiffness and wave reflection \[[@B48]\]. Although heart rate is known to greatly influence AI, it often can be corrected for an index normalized for heart rate of 75 beats per minute \[[@B49]\]. A meta-analysis showed AI to be an independent predictor of cardiovascular events and all-cause mortality \[[@B50]\]. AI can be influenced by mean arterial pressure, age, sex, and heart rate. Different from PWV which evaluates the hardness of the arteries between two recording points, AI can quantitatively reflect the elastic of the overall arterial system \[[@B51]\] and has become an important index to evaluate arterial compliance. Increase of AI suggested a hardening of the arteries and is used in clinical research due to its simple and convenient measurement. It was found that AI was more predictive for cardiovascular events than systolic blood pressure, diastolic blood pressure, or pulse pressure \[[@B52]\].

Pulse pressure (PP), with simple and convenient measurement, is widely used as roughly reflection of arterial stiffness, and increased PP showed increased arterial stiffness \[[@B8]\].

The large artery elasticity index (C1) and small artery elasticity index (C2) obtained by the pulse waveform analysis of the radial artery are two of the parameters of arterial elasticity, getting through the analysis of the radial artery diastolic blood pressure pulse waveform. Studies suggested that C1 and C2 were better than the traditional blood pressure detection for clinical application of early recognition of the cardiovascular disease \[[@B53]\], and C1 and C2 were independently associated with cardiovascular disease \[[@B54], [@B55]\]. However, there is some doubt that radial artery derived compliance measures truly represent systemic vascular compliance \[[@B56]\].

Most importantly, the common limitation of CAP, AI, C1, or C2 is the lack of reference values and adequate evidence to date, therefore limiting the current widely clinical application.

4. Measurement of Limb Artery-Ankle Brachial Index (ABI) {#sec4}
========================================================

ABI concept was proposed by Winsor in the 50s in twentieth Century, which was originally proposed as a noninvasive diagnostic technique for peripheral arterial disease (PAD) \[[@B57]\]. In 1982, ABI value less than or equal to 0.90 was identified as the diagnostic criteria of lower extremity PAD \[[@B58]\]. ABI is a simple, inexpensive evaluation of peripheral arterial disease and peripheral arterial stiffness and is a predictor of cardiovascular disease events \[[@B59]\]. The peripheral arterial disease guidelines proposed ABI normal value of 1.00--1.40 and ABI less than or equal to 0.90 as abnormal; ABI \> 1.40 showed poor blood vessel elasticity \[[@B60]\]. Studies have shown that low ABI (ABI \< 0.9) was related to the severity and degree of coronary artery disease and related to increased risk in recurrent of major cardiovascular events \[[@B61]\]. The risk of cardiovascular events increased independently of conventional risk factors in people with ABI equal or less than 0.90 \[[@B62]\]. In addition, high ABI values (\>1.40 or incompressible) were correlated with greater left ventricular mass measured by cardiac magnetic resonance \[[@B63]\]. Furthermore, adding ABI less than or equal to 0.9 to traditional risk factors can improve the prediction value of major cardiovascular events \[[@B64]\]. And another meta-analysis found that ABI was able to improve the accuracy of cardiovascular risk prediction better than the Framingham risk score \[[@B65]\]. Thus, ABI with the advantages of low cost, simple, easy operation, and good repeatability can be used in combination with the comprehensive risk factors to screen population by noninvasive, automatic detection and analysis system of vascular apparatus. However, in people with severe arterial calcification or vascular occlusion, the value of ABI may be abnormal.

5. Evaluation of Carotid Atherosclerosis {#sec5}
========================================

Ultrasound imaging technique as a noninvasive detection for clinical evaluation of carotid plaque (CP), carotid stenosis, and carotid artery intima-media thickness carotid (CIMT) is widely used. Ultrasound detection of carotid atherosclerotic lesions can be used as the observation window of the whole vascular bed atherosclerosis and can observe early atherosclerotic lesions dynamically. Its operating convenience, low cost, and good reproducibility made it a noninvasive screening of some high-risk and asymptomatic vascular disease patients \[[@B8]\]. Although CIMT did not consistently improve risk classification of individuals, the study found that CIMT was a significant and independent predictor of cardiovascular events \[[@B66]\]. High resolution multidetector row computed tomography angiography (CTA) can accurately assess plaque composition due to its advantages of rapid examination, relatively low cost, and being capable of measuring the absolute density as well as accurate identification and quantification of calcification, but for the identification of lipid core and plaque bleeding there is still lack of specificity \[[@B67]\]. High resolution magnetic resonance imaging (MRI) can describe the characteristics of carotid artery plaque, identify and measure plaque composition (lipid rich core, fibrous cap thickness, plaque bleeding and calcification, etc.), and detect vulnerable plaque. Compared with other imaging techniques, MRI has very high sensitivity and specificity for the identification and detection of plaque composition. However, the high cost, more contraindications, limited availability, and checking for a long time of MRI made it unable to realize the purpose of screening \[[@B67]\].

Whether CIMT and CP are distinct phenotypes or represent a different stage of atherosclerotic development is unclear. Some studies indicated that common CIMT can independently predict CP occurrence and suggested that increased CIMT might occur in an earlier phase of the atherosclerotic process \[[@B68], [@B69]\]. However, another study showed that increased CIMT is not an independent predictor of CP development although these atherosclerotic phenotypes often coexist and share some common vascular determinants. The result may suggest a distinct mechanism leading to formation of incident CP, rather than a continuum of the development of CP from CIMT \[[@B70]\]. In addition, accumulating evidences suggest that, although CIMT and CP, two phenotypes of carotid atherosclerosis, may share some common mechanisms, their predictive power of cerebrovascular disease (CVD) risk differs. In the ARIC study, the risk of coronary heart disease can be improved by adding plaque and CIMT to the traditional risk factors \[[@B71]\]. Both increased CIMT and CP were useful prognosticators to predict long term future cardiovascular events \[[@B72]\] and were associated with increased risk of ischemic stroke \[[@B73]\] and can be useful predictors of prevalence and severity of coronary artery disease \[[@B74]\]. However, CIMT measurement alone without CP presence or CP burden measures has limited value in risk prediction \[[@B75]\].

An article summarizing studies on CIMT and CP showed that CP was a better marker of CVD risk than CIMT and combined CIMT with CP assessment appear better than either measure alone \[[@B76]\]. Meta-analysis showed that CP, compared with CIMT, had a higher diagnostic accuracy for the prediction of future coronary artery disease events and cardiovascular events \[[@B77]\]. Evidence supporting a role for CIMT measurement in individual patients is poor. However, assessment of CP for the presence and volume seems much more promising for directing primary prevention strategies to those who will benefit from it \[[@B78]\].

6. Coronary Artery Calcium Score (CACS) {#sec6}
=======================================

CACS can be used for early diagnosis of coronary heart disease, review, and follow-up after treatment, screening for cardiovascular disease and high-risk population, and coronary artery CT angiography is the main noninvasive method for quantitative coronary artery calcified plaque at present \[[@B79]\]. CACS is commonly used to evaluate the severity of coronary artery calcification, and there are three methods: namely, Agatston integral, volume integral, and mass integral. Coronary artery calcification was quantified as a numerical value and Agatston integral was mostly used as a quantitative parameter of CACS \[[@B80]\]. CACS was used to evaluate subclinical disease and can improve the predictive value of cardiovascular events. Studies found that CACS was an independent predictor of coronary heart disease or cardiovascular events in the middle risk group \[[@B81]\]; in addition, in patients with no coronary artery calcification the future risk of cardiovascular events was very low \[[@B82]\].

7. Ambulatory Blood Pressure Monitoring (ABPM) and Dynamic Electrocardiography (ECG, Holter) Monitoring {#sec7}
=======================================================================================================

The ambulatory blood pressure recording instrument is composed of a transducer, a miniature recording box, and a recovery system and can automatically store data within 24 hours of the day and night, including systolic blood pressure, diastolic blood pressure, mean arterial pressure, heart rate, and the highest and lowest values. The 2013 European updated guidelines on hypertension stressed the importance of ABPM for the prognosis of clinical cardiovascular events, especially for clinic blood pressure and family pressure in apparent inconsistency, night hypertension, and blood pressure variability assessment \[[@B46]\]. 24-hour ABPM parameters were related to arterial function parameters and can predict future cardiovascular events, especially stroke \[[@B83]\].

The study of dynamic electrocardiogram was initiated in 1957 by Holter and first applied in the monitoring of cardiac electrical activity, thus also called Holter ECG. It can continuously record the daily activity under the condition of 24 hours of ECG changes, is noninvasive and easy to operate, and is widely used in clinical practice. The results of Holter ECG include heart rate, arrhythmia analysis, ST-T segment analysis, and analysis of heart rate variability. Statement of clinical application of ECG and dynamic ECG in the United States made dynamic ECG monitoring an important indication \[[@B84]\].

8. Detection of Biomarkers {#sec8}
==========================

About early assessment of vascular disease, in addition to direct or indirect imaging techniques or noninvasive evaluation techniques for arterial stiffness, there are also many risk biomarkers of vascular disease, including traditional biomarkers and some new markers found in recent years. Basic research showed that vascular endothelial cells are an important paracrine organ and play a variety of physiological roles through the secretion or release of a series of biologically active medium, and vascular endothelial dysfunction can lead to some abnormal indicators. Therefore, the detection of biomarkers can be used as the evaluation index of endothelial dysfunction \[[@B8]\]. In addition, biomarkers of vascular disease, such as N-terminal probrain natriuretic peptide (NT-proBNP), high sensitivity C-reactive protein (hs-CRP), homocysteine, fibrinogen, triglycerides, uric acid, intercellular adhesion molecules-1, interleukin-6, and serum albumin, were also involved in the pathological progression of atherosclerosis \[[@B8], [@B85]\]. The study found that CAVI and NT-proBNP were higher in patients with hypertension and coronary heart disease, and the two were significantly associated \[[@B86]\]. Our research team previous studies also found that different disease states of population, its vascular indicators, and biological indicators were different and were influenced by many kinds of related factors. For example, hypertension, diabetes, coronary heart disease, and lower extremity arterial disease patients CAVI levels were higher and related to blood lipids, hs-CRP, NT-proBNP, and homocysteine \[[@B30]--[@B34]\]. For people with no known cardiovascular disease, it is found that the use of CRP or fibrinogen to assess risk can be helpful for the prevention of cardiovascular events \[[@B87]\]. A consensus panel presented that these new clinical examinations such as glycosylated hemoglobin, trace urinary albumin, C-reactive protein, lipoprotein associated phospholipase, coronary artery calcification, carotid intima-media thickness, and ankle brachial index can be used in cardiovascular risk prediction \[[@B88]\]. The American Heart Association also recommends that, in addition to traditional risk factors, family history, glycosylated hemoglobin, and microalbumin urine can be used to predict the risk of coronary heart disease \[[@B27]\]. A study including 30 markers finally screened 3 markers, namely, N-terminal probrain natriuretic peptide, C-reactive protein, and sensitive troponin I. Adding these three markers to the traditional risk prediction model can improve the predictive value of cardiovascular events in the future 10 years \[[@B89]\]. A follow-up study found that coronary heart disease can reduce the incidence rate of 66% mainly attributed to the change of risk factors, the favorable changes in cholesterol accounted for 32%, and blood pressure, smoking, and exercise were 14%, 13%, and 9%, respectively \[[@B90]\]. Therefore, the identification of new vascular related biomarkers and early intervention can reduce the incidence of vascular disease.

9. Genetic Evaluation {#sec9}
=====================

Arteriosclerosis is not the patent of the modern society, its existence precedes the modern civilized society and the present risk factor \[[@B91]\], and traditional risk factors just are only part of arterial stiffness and genetic factors also occupy a part. The study, which was found by CT scans of the mummy in 3300 BC, was the first document of the carotid artery atherosclerosis, which represented the earliest records of human atherosclerosis \[[@B92]\]. Study found that atherosclerosis was actually the basis of aging, early after began to degenerate early after birth and progress with age. The interaction between genes and environment played an important role in the occurrence and development of atherosclerosis, genes created the vulnerability of atherosclerosis, and whether or when clinical atherosclerosis occurs was determined by environment \[[@B93]\].

Hyperhomocysteinemia (HHcy) is characterized by elevated plasma total homocysteine levels and associated with increased risk of cardiovascular disease and stroke \[[@B94]\]. Studies have found that Hcy and CAVI were significantly positively correlated in patients with vascular disease \[[@B31]\], and HHcy patients endothelial function was impaired \[[@B95]\]. Methylenetetrahydrofolate reductase (MTHFR) is a key enzyme in the folate pathway and can mediate the clearance of homocysteine in human body. The genetic polymorphisms of CT and TT in the 677th genes of MTHFR gene resulted in the change of MTHFR enzyme activity, leading to metabolic disturbance of folic acid. Studies showed that C677T gene polymorphism can be used as a useful screening marker for severe HHcy \[[@B96]\]. The relationship between metalloproteinase matrix (MMP) family gene polymorphism and coronary heart disease (CHD) has been widely studied, and genetic defects lead to MMPs activation overexpression playing a key role in the pathogenesis of CHD. Studies indicated that extracellular matrix metabolism regulation abnormalities play a substantial role in vascular remodeling \[[@B97]\]. MicroRNAs (miRNAs) are an important regulator of endothelial function by fine tuning of gene expression. The specific expression of miRNAs combined together can be used to identify the developmental stages of disease, and intrinsic biological information obtained by miRNAs may be transformed into a new treatment method \[[@B98]\]. It was found that the gene variant of apolipoprotein E gene is the strongest signal of low density lipoprotein cholesterol and also related to cardiovascular risk factors such as high density lipoprotein cholesterol, triglycerides, inflammatory biomarkers C-reactive protein, and CIMT \[[@B99]\]. The peroxisome proliferator-activated receptor (PPARG) is a nuclear hormone receptor and plays an important role in obesity, insulin resistance, and other metabolic diseases as well as CHD. PPARG has two common genetic polymorphisms, namely, P12A and C161T. Recent studies showed that both of these two polymorphisms may affect individual susceptibility to metabolic disease and CHD risk, but there have also been studies which found that C161T PPARG slightly increased the sensitivity of coronary heart disease, and the P12A PPARG was not associated with the risk of CHD \[[@B100]\]. In a study, genetic risk score based on 13 single nucleotide polymorphisms associated with coronary heart disease can be able to identify 20% of the individuals in the European pedigree with an increased risk of coronary heart disease events by 70% \[[@B101]\]. Therefore, it will be possible to provide theoretical basis for gene targeted therapy by using genetic evaluation method to detect the genetic loci of vascular lesions.

All the technologies of vascular early detection mentioned above were summarized within a table (see [Table 1](#tab1){ref-type="table"}), including the region of interest, advantages, and disadvantages about all kinds of measurement for vascular health.

10. Establishment and Prospect of Comprehensive Evaluation System of Vascular Disease {#sec10}
=====================================================================================

Based on the preliminary research foundation, in 2006, our research team released the first report of Chinese vascular disease early detection technology application guide \[[@B102]\]. The guideline covered a variety of effective indicators for early assessment of vascular disease. Then according to the 2006 guideline recommendation, we conducted a series of studies, including the vascular function in different diseases, different vascular assessment techniques and biomarker research, and drug intervention studies. After further researches, the guideline was updated in 2011, and some new vascular assessment techniques were added \[[@B25]\]. The evaluation system combined with a variety of assessment techniques from different levels of vascular structure and function, such as biomarkers, imaging indexes, and noninvasive arterial stiffness. There were relevant recommendations published by the European updated guidelines in 2013; for example, CIMT was recommended, CF-PWV was used to evaluate arterial stiffness, and ABI can be used to assess peripheral arterial disease \[[@B46]\]. Similarly, the United States also published a guideline and recommended that the evaluation of coronary artery calcium score, ABI, family history, or high sensitivity C reactive protein was considerable when it was based on treatment decisions; however, it is not sure whether the carotid IMT can be used as a routine clinical examination to assess the risk of a first cardiovascular event \[[@B103]\].

At present, there are a variety of cardiovascular risk prediction models \[[@B104]\], to predict the risk of cardiovascular events in the future, with the famous Framingham scoring system and Reynolds risk assessment system. However, these scoring systems are assessing the traditional risk factors for cardiovascular risk, such as age, sex, body mass index, smoking, family history, systolic blood pressure, diabetes, total cholesterol, high density lipoprotein cholesterol, and high sensitivity C-reactive protein, and did not directly assess the blood vessels that cause disease. In addition, these models predict the risk of cardiovascular disease over the next 10 years or even longer, while there is lack of a recent risk assessment in order to carry out interventions and prevent the occurrence of events. Furthermore, present assessment of vascular health status, limited to a single indicator, although there are multiple indicators, did not carry out effective combination and even classification of various indicators. Therefore, the new vascular health classification, on the basis of traditional risk factors, superimposed the vascular structure and function evaluation indicators recommended in the guidelines, directly regarding the blood vessel as the target, and conducted the grading management, to comprehensively assess the vascular health status, which also reflects the current hot topic, precision medicine \[[@B38]\].
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Summarizing early evaluation system of vascular health.

  Techniques                                     Region of interest                                     Advantages                                                                   Disadvantages
  ---------------------------------------------- ------------------------------------------------------ ---------------------------------------------------------------------------- ----------------------------------------------------------------------------------
  *Vascular endothelial function*                Vascular endothelium                                                                                                                 
   Coronary angiography \[[@B7]\]                Coronary artery                                        Gold standard                                                                Invasive, difficult, time consuming with high cost
   FMD \[[@B17], [@B18], [@B20], [@B21]\]        Conduit brachial artery                                Noninvasive, simple, most used                                               Technical requirements, Multiple influencing factors
   PAT-RHI \[[@B18], [@B20], [@B21]\]            Finger microvasculature                                Automatic detection, simple operation                                        More data on predictive value
  *Arterial stiffness*                                                                                                                                                                
   PWV \[[@B22], [@B23]\]                        Large artery function                                  Gold standard                                                                Dependent on blood pressure
   CAVI \[[@B29], [@B30]\]                       Large artery function and structure                    Independent of blood pressure                                                Influenced by lower ABI value, more data on predictive value
   CAP \[[@B39]--[@B43]\]                        Cardiac catheterization                                Directly                                                                     Invasive
  Systolic radial or carotid artery waveforms    Noninvasive, easy conduction                           Need more investigation                                                      
   AI \[[@B41], [@B47], [@B50], [@B51]\]         Systolic radial or carotid artery waveforms analysis   Noninvasive, automatically detected                                          Lack of reference value, need more investigation
   C1/C2 \[[@B53]--[@B55]\]                      Diastolic radial artery waveform analysis              Noninvasive, automatically detected                                          Lack of reference value, need more investigation
  *ABI* \[[@B59], [@B60], [@B65]\]               Peripheral limb artery                                 Gold standard of PAD, predictor of CVD, easy operation, good repeatability   Not suitable for people with severe arterial calcification or vascular occlusion
  *Carotid atherosclerosis*                                                                                                                                                           
   CIMT \[[@B75], [@B76], [@B78]\]               Structure of carotid artery                            Noninvasive, easy operation                                                  Multiple location of measurements
   CP \[[@B75], [@B76]\]                         Structure of carotid artery                            Noninvasive, easy operation                                                  Plaque multiple variation
  *CACS* \[[@B79], [@B80]\]                      Coronary artery structure                              High cost                                                                    Prediction of CVD
  *ABPM and Holter* \[[@B46], [@B83], [@B84]\]   Ambulatory monitoring of blood pressure and ECG        Low cost, real-time monitoring                                               Prognosis of CVD
  *Biomarkers* \[[@B27], [@B88], [@B89]\]        Blood indicators                                       Simple, inexpensive, good reproducibility                                    Need further validation
  *Genetic evaluation* \[[@B91]--[@B93]\]        Genetic loci                                           Gene targeted therapy                                                        Need further validation
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